Last checked at 12 Oct 2023 07:00
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Investor Presentation
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that Creo will deliver a presentation providing an overview of the Company at a hybrid event in London hosted by the UK Individual Shareholders' Society (ShareSoc) on Thursday 19 October 2023 and available to ShareSoc members via the link below:
https://www.sharesoc.org/sharesoc-walbrook-pr-healthcare-companies-hybrid-event-london-19-october-2023-5pm/
Craig Gulliford, Chief Executive Officer will deliver an "in-person" presentation which will also be streamed live (and recorded), allowing ShareSoc members to watch virtually. No new material information will be disclosed in the presentation.
An online presentation covering the Company's interim results for the six months ended 30 June 2023, and presented on 12 September 2023, is available for all investors on the Investor Meet Company platform and can be accessed via this link: https://www.investormeetcompany.com/investor/meeting/investor-presentation-421
Enquiries:
Creo Medical Group plc | www.creomedical.com |
Richard Rees (CFO) | +44 (0)1291 606 005 |
Cavendish Securities plc | +44 (0)20 7397 8900 |
Stephen Keys / Camilla Hume (NOMAD) | |
Michael Johnson (Sales) | |
Numis Securities Limited (Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown | +44 (0)20 7260 1000 |
| |
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
Paul McManus / Sam Allen / Phillip Marriage | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082 |
About Creo Medical
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com